|
|
{{if listFind(vars.channel_names, "MSIF News")}} {{endif}}  {{if listFind(vars.channel_names, "MSIF News")}} {{endif}} {{if listFind(vars.channel_names, "MSIF News")}} 
MSIF News
{{endif}}
|
{{if listFind(vars.channel_names, "People With MS News")}} {{endif}}  {{if listFind(vars.channel_names, "People With MS News")}} {{endif}} {{if listFind(vars.channel_names, "People With MS News")}} 
People with MS News
{{endif}}
|
{{if listFind(vars.channel_names, "Research News")}} {{endif}}  {{if listFind(vars.channel_names, "Research News")}} {{endif}} {{if listFind(vars.channel_names, "Research News")}} 
Research News
{{endif}}
|
{{if listFind(vars.channel_names, "MS Society News")}} {{endif}}  {{if listFind(vars.channel_names, "MS Society News")}} {{endif}} {{if listFind(vars.channel_names, "MS Society News")}} 
MS News
{{endif}}
|
|
|
|
Making Connections
Tysabri announcement
The European Medicines Agency (EMEA) has recommended that Tysabri (natalizumab) should be made available as a treatment for relapsing remitting multiple sclerosis (MS), to delay the progression of disability and reduce the frequency of relapses.
Read more
|
{{if listFind(vars.channel_names, "MSIF News")}}
|
|
MSIF News
 |
 |
| Summaries of new MSIF activities, events, projects, programmes, resources, publications and more. |
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "People With MS News")}}
|
|
People with MS News
|
|
| Summaries of news, views and achievements from people with MS around the world. |
FDA Advisory Committee Recommends Tysabri®'s Return to Market
source: USA National MS Society
Update: March 22, 2006— Biogen Idec and Elan Corporation announced today that the U.S. Food and Drug Administration (FDA) informed them that the Agency will extend its regulatory review of Tysabri® (natalizumab) as a treatment for multiple sclerosis by up to 90 days.
read more
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "Research News")}}
|
|
Research News
|
|
| Summaries of all the latest research findings on MS selected by a team based at the Institute of Neurology, London. |
Stroke after initiation of interferon-beta treatment for relapsing-remitting disseminated white matter disease
This paper reports the case of a 34-year-old female patient satisfying the McDonald criteria of multiple sclerosis. After introduction of INF-beta treatment, she developed an ischemic cerebral infarction. All diagnostic evaluations and the clinical course revealed evidences for a primary angiitis of the central nervous system. The authors then discuss the possible worsening due to inappropriate INF-beta treatment in cerebral angiitis.
authors: Bosche B, Dohmen C, Impekoven P, Weber OZ, Reske D, Rubbert A, Jacobs AH, Petereit HF
source: Acta Neurol Scand. 2006 Jun;113(6):433-6.
read more
The relationship between MRI and PET changes and cognitive disturbances in MS
This paper discusses the use of new emerging imaging techniques that embrace such abnormalities as normal appearing white matter (NAWM) and cortical grey matter in order to achieve better correlation with cognitive dysfunction of patients with MS.
authors: Sorensen PS, Jonsson A, Mathiesen HK, Blinkenberg M, Andresen J, Hanson LG, Ravnborg M
source: J Neurol Sci. 2006 Apr 27; [Epub ahead of print]
read more
Cognitive impairment in newly diagnosed multiple sclerosis patients: A 4-year follow-up study
This is a 4 year follow-up study of cognitive functions in newly diagnosed MS. At the end of the observation 33-34% of the patients had cognitive impairment. Thirty percent of the patients were on disablement pension, 34% received social services in relation to work and 13% had home care. Methodological problems are discussed, especially the practice effect and the importance of identifying sensitive and stable test measures.
authors: Jonsson A, Andresen J, Storr L, Tscherning T, Soelberg Sorensen P, Ravnborg M
source: J Neurol Sci. 2006 Apr 25; [Epub ahead of print]
read more
Featured Research
http://www.msif.org/en/research/ms_research_news/treatments_for_s.html
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "MS Society News")}}
|
|
MS News
|
|
| summaries of MS news from websites around the world. |
Featured News
National Institute for Clinical Excellence, UK, launch new guidelines on the management of the MS.
source: UK MS Society
The UK MS Society has welcomed the launch of the new National Institute for Clinical Excellence guidelines for the NHS on the management of the disease on Wednesday 26 November 2003.
Mike O'Donovan, chief executive of the UK MS Society, said, "The new guidelines are the most far-reaching step ever taken towards better management of MS. They promote good practice, bring together evidence and guidance for care and treatment. They offer links beyond healthcare into social care and employment. They also set a benchmark which will inform the National Service Framework on Long Term Conditions, due in 2005".
read more
|
{{endif}}
|
|
Tell a friend
The email you subscribed with us is {{print email}}
Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To ammend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email addres, contact details and subscribe to our free publications.
If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate
If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here
Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org
|
|
